BET inhibitor molibresib for the treatment of advanced solid tumors: Final results from an open-label phase I/II study.
Year: 2020
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Sophie Cousin, Jean-Yves Blay, Irene Braña Garcia, Johann S. De Bono, Christophe Le Tourneau, Victor Moreno, Jose Manuel Trigo, Christine L. Hann, Arun Azad, Seock-Ah Im, Geraldine Ferron-Brady, Antara Datta, Yuehui Wu, Thierry Horner, Brandon Edward Kremer, Arindam Dhar, Peter J. O'Dwyer, Geoffrey Shapiro, Sarina Anne Piha-Paul
Institutions: Institut Bergonié, Centre Léon Bérard, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, Institute of Cancer Research, Royal Marsden Hospital, Institut Curie, Hospital Universitario Fundación Jiménez Díaz, Instituto de Investigación Biomédica de Málaga, Johns Hopkins University, Peter MacCallum Cancer Centre, Seoul National University Hospital, GlaxoSmithKline (United States), Abramson Cancer Center, University of Pennsylvania, Brigham and Women's Hospital, Harvard University, Dana-Farber Cancer Institute, Dana-Farber Brigham Cancer Center, The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W3028741702